NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moder
NKTR Nektar Therapeutics announces start of phase 3 zenith Ad program evaluating novel regulatory T-cell biologic rezpegaldesleukin in moderate-to-severe atopic dermatitis Nektar Therapeutics - initial phase 3 topline data expected mid-2028; BLA submission targeted for 2029 - Zenith Ad program to enroll 1,530 patients across three phase 3 studies
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.